Loading...

Moleculin Biotech

Nasdaq:MBRX
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MBRX
Nasdaq
$54M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. The last earnings update was 44 days ago. More info.


Add to Portfolio Compare Print
  • Moleculin Biotech has significant price volatility in the past 3 months.
MBRX Share Price and Events
7 Day Returns
-4%
NasdaqCM:MBRX
0.6%
US Biotechs
1.4%
US Market
1 Year Returns
-30.2%
NasdaqCM:MBRX
-4.9%
US Biotechs
4.9%
US Market
MBRX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Moleculin Biotech (MBRX) -4% 8.1% 41.3% -30.2% -81.9% -
US Biotechs 0.6% 2.3% -1.8% -4.9% 22.2% 9.1%
US Market 1.4% 3.8% 3.5% 4.9% 44.8% 40.1%
1 Year Return vs Industry and Market
  • MBRX underperformed the Biotechs industry which returned -4.9% over the past year.
  • MBRX underperformed the Market in United States of America which returned 4.9% over the past year.
Price Volatility
MBRX
Industry
5yr Volatility vs Market
Related Companies

MBRX Value

 Is Moleculin Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Moleculin Biotech. This is due to cash flow or dividend data being unavailable. The share price is $1.2.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Moleculin Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Moleculin Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:MBRX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.51
NasdaqCM:MBRX Share Price ** NasdaqCM (2019-06-25) in USD $1.2
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,095 Publicly-Listed Companies 17.73x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Moleculin Biotech.

NasdaqCM:MBRX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:MBRX Share Price ÷ EPS (both in USD)

= 1.2 ÷ -0.51

-2.34x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Moleculin Biotech is loss making, we can't compare its value to the US Biotechs industry average.
  • Moleculin Biotech is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Moleculin Biotech's expected growth come at a high price?
Raw Data
NasdaqCM:MBRX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.34x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
35.6%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.02x
United States of America Market PEG Ratio Median Figure of 2,133 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Moleculin Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Moleculin Biotech's assets?
Raw Data
NasdaqCM:MBRX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.43
NasdaqCM:MBRX Share Price * NasdaqCM (2019-06-25) in USD $1.2
United States of America Biotechs Industry PB Ratio Median Figure of 431 Publicly-Listed Biotechs Companies 2.98x
United States of America Market PB Ratio Median Figure of 5,255 Publicly-Listed Companies 1.79x
NasdaqCM:MBRX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:MBRX Share Price ÷ Book Value per Share (both in USD)

= 1.2 ÷ 0.43

2.81x

* Primary Listing of Moleculin Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Moleculin Biotech is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Moleculin Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Moleculin Biotech has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MBRX Future Performance

 How is Moleculin Biotech expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
35.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Moleculin Biotech expected to grow at an attractive rate?
  • Moleculin Biotech's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Moleculin Biotech's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Moleculin Biotech's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:MBRX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:MBRX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 35.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:MBRX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:MBRX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 21 13 2
2022-12-31 11 -3 2
2021-12-31 0 -22 2
2020-12-31 0 -19 2
2019-12-31 0 -18 2
NasdaqCM:MBRX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -13 -14
2018-12-31 -12 -12
2018-09-30 -11 -12
2018-06-30 -10 -13
2018-03-31 -9 -11
2017-12-31 -7 -10
2017-09-30 -6 -8
2017-06-30 -5 -7
2017-03-31 -5 -4
2016-12-31 -4 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Moleculin Biotech's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Moleculin Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:MBRX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Moleculin Biotech Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:MBRX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.24 0.24 0.24 1.00
2022-12-31 -0.06 -0.06 -0.06 1.00
2021-12-31 -0.44 -0.44 -0.44 1.00
2020-12-31 -0.45 -0.45 -0.45 1.00
2019-12-31 -0.49 -0.49 -0.49 1.00
NasdaqCM:MBRX Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.51
2018-12-31 -0.46
2018-09-30 -0.50
2018-06-30 -0.57
2018-03-31 -0.55
2017-12-31 -0.53
2017-09-30 -0.49
2017-06-30 -0.47
2017-03-31 -0.33
2016-12-31 -0.40

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Moleculin Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Moleculin Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Moleculin Biotech has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MBRX Past Performance

  How has Moleculin Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Moleculin Biotech's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Moleculin Biotech does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Moleculin Biotech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Moleculin Biotech's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Moleculin Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Moleculin Biotech Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:MBRX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -13.99 5.43 11.42
2018-12-31 -11.88 5.23 9.73
2018-09-30 -12.28 4.96 9.09
2018-06-30 -13.10 5.05 8.82
2018-03-31 -11.40 4.63 5.10
2017-12-31 -9.81 4.09 4.55
2017-09-30 -8.04 3.52 3.14
2017-06-30 -6.61 3.11 2.58
2017-03-31 -3.92 2.92 2.16
2016-12-31 -3.93 2.38 1.50
2015-12-31 -1.80 1.15 0.63

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Moleculin Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Moleculin Biotech has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Moleculin Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Moleculin Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Moleculin Biotech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MBRX Health

 How is Moleculin Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Moleculin Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Moleculin Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Moleculin Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Moleculin Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Moleculin Biotech has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Moleculin Biotech Company Filings, last reported 2 months ago.

NasdaqCM:MBRX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 14.68 0.00 8.78
2018-12-31 14.27 0.00 7.13
2018-09-30 14.97 0.00 8.60
2018-06-30 16.75 0.00 11.72
2018-03-31 20.57 0.00 13.11
2017-12-31 17.12 0.00 7.71
2017-09-30 18.65 0.00 8.74
2017-06-30 19.27 0.00 9.27
2017-03-31 16.14 0.11 8.88
2016-12-31 14.96 0.30 5.01
2015-12-31 -0.74 0.45 0.03
  • Moleculin Biotech has no debt.
  • Moleculin Biotech currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Moleculin Biotech has less than a year of cash runway based on current free cash flow.
  • Moleculin Biotech has less than a year of cash runway if free cash flow continues to grow at historical rates of 54% each year.
X
Financial health checks
We assess Moleculin Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Moleculin Biotech has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MBRX Dividends

 What is Moleculin Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Moleculin Biotech dividends.
If you bought $2,000 of Moleculin Biotech shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Moleculin Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Moleculin Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:MBRX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2012 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:MBRX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Moleculin Biotech has not reported any payouts.
  • Unable to verify if Moleculin Biotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Moleculin Biotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Moleculin Biotech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Moleculin Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Moleculin Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Moleculin Biotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MBRX Management

 What is the CEO of Moleculin Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Wally Klemp
COMPENSATION $1,345,675
AGE 58
TENURE AS CEO 3.9 years
CEO Bio

Mr. Walter V. Klemp, also known as Wally, founded Moleculin Biotech, Inc. in July 2015 and has been its Chief Executive Officer since July 2015 and President since August 23, 2017. He is a Founder of Soliton, Inc. and serves as its Executive Chairman since July 2018. Mr. Klemp served as the President and Treasurer at Soliton, Inc. until July 2018. He served as Chief Executive Officer of Soliton, Inc. since November 2011 until July 2018, where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. He co-founded Moleculin LLC and served as its Part-Time Chief Executive Officer. Mr. Klemp served as President and Chief Executive Officer of LumaTherm, Inc. (formerly Tyrell Inc.). He directed the Tyrell's development of its key product, Zeno, a medical device, intended for over-the-counter treatment of acne, that utilizes revolutionary new technology. Mr. Klemp served as President and Chief Executive Officer of Zeno Corporation from 2004 to April 2011, where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. Mr. Klemp founded Syntronyx Global Corporation. He served as the Chief Executive Officer of Syntronyx Global Corporation from 2001 to 2002. Prior to Syntronyx, he founded Drypers Corporation and served as its Chairman & Chief Executive Officer from 1987 to 2000. He started the Drypers Corporation with a college friend in his basement in the mid-1980s and eventually built it into a $400 million publicly traded company, with 2,400 employees and operations in seven countries. Prior to Drypers, Mr. Klemp was a CPA with Coopers & Lybrand (now PricewaterhouseCoopers). He has established a strong history of entrepreneurial achievement. Throughout his career, he has founded three companies and filed six U.S. patents. He has been Chairman of Moleculin Biotech, Inc. since July 2015. Mr. Klemp served as Chairman of Moleculin, L.L.C. He served as the chairman of Syntronyx Global Corporation from 2001 to 2002. He served as a Director of Drypers Corporation since February 1987. He serves as a Director of Soliton, Inc. He served as Member of Business Advisory Board at Moleculin Biotech, Inc. While a student, he was also recognized as Oregon's state champion orator. Mr. Klemp earned a B.A. from Lewis & Clark College, graduating with honors as the business school's “Outstanding Accounting Scholar.

CEO Compensation
  • Wally's compensation has increased whilst company is loss making.
  • Wally's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Moleculin Biotech management team in years:

2.8
Average Tenure
62
Average Age
  • The tenure for the Moleculin Biotech management team is about average.
Management Team

Wally Klemp

TITLE
Founder
COMPENSATION
$1M
AGE
58
TENURE
3.9 yrs

Jon Foster

TITLE
Executive VP & CFO
COMPENSATION
$846K
AGE
54
TENURE
2.8 yrs

Don Picker

TITLE
Chief Scientific Officer
COMPENSATION
$439K
AGE
72
TENURE
1.8 yrs

Waldemar Priebe

TITLE
Co-Founder and Chairman of Scientific Advisory Board

Rob Shepard

TITLE
Chief Medical Officer
AGE
66
TENURE
3 yrs

Sandra Silberman

TITLE
Chief Medical Officer of New Products
AGE
62
TENURE
1.6 yrs

Jacqueline Northcut

TITLE
Consultant
COMPENSATION
$69K
AGE
56
TENURE
1.9 yrs

Louis Ploth

TITLE
Independent Advisor
COMPENSATION
$118K
AGE
64
TENURE
2.8 yrs
Board of Directors Tenure

Average tenure and age of the Moleculin Biotech board of directors in years:

1.7
Average Tenure
66
Average Age
  • The average tenure for the Moleculin Biotech board of directors is less than 3 years, this suggests a new board.
Board of Directors

Waldemar Priebe

TITLE
Co-Founder and Chairman of Scientific Advisory Board

Robert George

TITLE
Independent Director
COMPENSATION
$107K
AGE
68
TENURE
3 yrs

Wally Klemp

TITLE
Founder
COMPENSATION
$1M
AGE
58
TENURE
3.9 yrs

Michael Cannon

TITLE
Independent Director
COMPENSATION
$101K
AGE
73
TENURE
3 yrs

John Climaco

TITLE
Lead Independent Director
COMPENSATION
$111K
AGE
49
TENURE
1.9 yrs

John Waymack

TITLE
Member of Scientific Advisory Board
AGE
66

Jorge Cortes

TITLE
Member of Scientific Advisory Board
TENURE
1.4 yrs

Elihu Estey

TITLE
Member of Scientific Advisory Board
TENURE
1.4 yrs

James Abbruzzese

TITLE
Member of Science Advisory Board
TENURE
0.4 yrs

Martin Tallman

TITLE
Member of Scientific Advisory Board
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Moleculin Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Moleculin Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MBRX News

Simply Wall St News

Who Really Owns Moleculin Biotech Inc (NASDAQ:MBRX)?

View our latest analysis for Moleculin Biotech NasdaqCM:MBRX Ownership_summary Mar 19th 18 Institutional Ownership Due to the big order sizes of institutional investors, a company's shares can experience large, one-sided momentum, driven by high volume of shares removed from, or injected into, the market. … Generally, an institutional ownership of 2.61%, in the case of MBRX, should not concern investors in terms of high stock volatility. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: Although MBRX has a low level of overall institutional ownership, active hedge funds still have a significant stake in the company.

Simply Wall St -

Is Moleculin Biotech Inc's (NASDAQ:MBRX) CEO Pay Fair?

See our latest analysis for Moleculin Biotech What has MBRX's performance been like? … Therefore I will use earnings as a proxy of Klemp's performance in the past year. … Normally I would use earnings and market cap to account for variations in performance, however, MBRX's negative earnings reduces the usefulness of my formula.

Simply Wall St -

Is Moleculin Biotech Inc (NASDAQ:MBRX) A Healthcare Leader?

In this article, I’ll take you through the sector growth expectations, as well as evaluate whether Moleculin Biotech is lagging or leading its competitors in the industry. … View our latest analysis for Moleculin Biotech What’s the catalyst for Moleculin Biotech's sector growth? … If your initial investment thesis is around the growth prospects of Moleculin Biotech, there are other biotech companies that have delivered higher growth, and perhaps trading at a discount to the industry average.

Simply Wall St -

Why Moleculin Biotech Inc's (MBRX) CEO Pay Matters To You

Check out our latest analysis for Moleculin Biotech What has MBRX performance been like? … Therefore I will use earnings as a proxy of Klemp's performance in the past year. … Usually I would look at market cap and earnings as a proxy for performance, however, MBRX's negative earnings lower the usefulness of my formula.

Simply Wall St -

Who Owns Most Of Moleculin Biotech Inc (MBRX)?

Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital. … Private Company Ownership Potential investors in MBRX should also look at another important group of investors: private companies, with a stake of 13.25%, who are primarily invested because of strategic and capital gain interests. … Institutional ownership in MBRX is not at a level that would concern investors.

Simply Wall St -

How Much Money Does Moleculin Biotech Inc (MBRX) Have Left?

Looking at MBRX’s latest financial data, I will gauge when the company may run out of cash and need to raise more money. … My cash burn analysis suggests that MBRX has a cash runway of 1.6 years, given its current level of cash holdings. … The outcome of my analysis suggests that if MBRX maintains the rate of opex growth, it will run out of cash in the upcoming years.

Simply Wall St -

MBRX Company Info

Description

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase I/II clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) in the United States and Poland. The company's flagship immune/transcription modulator is WP1066, a STAT3 inhibitor, which is in Phase I clinical trial for the treatment of brain tumor, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma in Poland; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122, a prodrug of 2-deoxyglucose to treat brain tumors and pancreatic cancer. In addition, it develops WP1234 for the treatment of pancreatic cancer. Further, the company engages in the preclinical development of other drug candidates, including other immune/transcription modulators and metabolism/glycosylation inhibitors. It has an agreement with the University of Iowa Pharmaceuticals for the development of a formulation for WP1732; collaboration with Dermin Sp. zoo for the development of WP1220; and collaboration with M.D. Anderson Cancer Center for the development of WP1732 and WP1066. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.

Details
Name: Moleculin Biotech, Inc.
MBRX
Exchange: NasdaqCM
Founded: 2015
$54,230,457
45,192,048
Website: http://www.moleculin.com
Address: Moleculin Biotech, Inc.
5300 Memorial Drive,
Suite 950,
Houston,
Texas, 77007,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM MBRX Common Stock Nasdaq Capital Market US USD 02. Jun 2016
DB MOL Common Stock Deutsche Boerse AG DE EUR 02. Jun 2016
Number of employees
Current staff
Staff numbers
11
Moleculin Biotech employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/26 01:12
End of day share price update: 2019/06/25 00:00
Last estimates confirmation: 2019/05/23
Last earnings filing: 2019/05/13
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.